Evidence map›Paper›PMID 41739347›Full record

ArticleJournal of materials science. Materials in medicine2026

A pH-responsive mesoporous Zn-MOF nanocarrier for efficient cisplatin delivery and inhibition of A549 cancer cells.

Xiaomei Ye, Shuzhen Lu, Hao Peng, Zhirong Huang, Chunyu Pan, Yayan Huang, Kangrui Yuan, Youfa Qin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaomei YeDongguan Key Laboratory of Precision Medicine Individualized Treatment Development, Department of Clinical Pharmacy, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China.
Shuzhen LuDongguan Key Laboratory of Precision Medicine Individualized Treatment Development, Department of Clinical Pharmacy, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China.
Hao PengDongguan Key Laboratory of Precision Medicine Individualized Treatment Development, Department of Clinical Pharmacy, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China.
Zhirong HuangDongguan Key Laboratory of Precision Medicine Individualized Treatment Development, Department of Clinical Pharmacy, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China.
Chunyu PanDongguan Key Laboratory of Precision Medicine Individualized Treatment Development, Department of Clinical Pharmacy, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China.
Yayan HuangDepartment of Pharmacy, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China. 13642384460@163.com.
Kangrui YuanCollege of Chemical Engineering, Nanjing Forestry University, Nanjing, China. kangrui.yuan@njfu.edu.cn.
Youfa QinDongguan Key Laboratory of Precision Medicine Individualized Treatment Development, Department of Clinical Pharmacy, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China. qinyoufaqwerty@163.com.

Funding

the Medical Scientific Research Foundation of Guangdong Province B2022026
6 · The paper itself

Abstract

Mesoporous metal-organic frameworks (MOFs) have the advantages of high specific surface area, tunable pore size, and favorable biocompatibility, making them promising candidates for drug delivery in cancer therapy. In this study, a series of mesoporous zinc-based MOF, constructed using cyclopentane dicarboxylic acid as the organic linker, was successfully synthesized via a surfactant-assisted solvothermal method. Surface characterization revealed that MOF-2 exhibited high surface area (1325 m

Indexed as

CisplatinDrug CarriersMetal-Organic FrameworksNanoparticlesZincA549 CellsAntineoplastic AgentsCell SurvivalDrug Delivery SystemsDrug LiberationHumansHydrogen-Ion ConcentrationPorosityAntineoplastic AgentsCisplatinDrug CarriersMetal-Organic FrameworksZinc

Identifiers

PMID41739347
PMCPMC12960383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.